Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children

Cancer Chemotherapy and Pharmacology

Volumn 28, Issue 6, 1991, Pages 455-460

  Boos, J ^a   Welslau, U ^b   Ritter, J ^a   Blaschke, G ^b   Schellong, G ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Institut fur Pharmazeutische Chemie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IFOSFAMIDE;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DRUG METABOLISM; ENANTIOMER; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; URINE LEVEL;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, GAS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN; IFOSFAMIDE; STEREOISOMERISM; SUPPORT, NON-U.S. GOV'T;

EID: 0025944604     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/BF00685822     Document Type: Article

References (36)

1. In vitro activation of isophosphamide (NSC-109 724), a new oxazaphosphorine, by rat liver microsomes
2. Studies on the human pharmacokinetics of ifosfamide (NCI-109 724)
3. Untersuchungen zum stereoselektiven Metabolismus von Ifosfamid
4. Metabolismus der Enantiomere des Zytostatikums Ifosfamid
5. Präparative Trennung der Ifosfamid-Enantiomere und ihre pharmakologisch-toxikologische Untersuchung
6. Ifostamide by continuous infusion to prevent encephalopathy
7. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide
8. Observations on the differential metabolism and biological activity of the optical isomers of cyclophosphamide
9. Stereoselectivity in the metabolism of the enantiomers of cyclophosphamide in mice, rats and rabbits
10. CNS-side effects induced by ifosfamide-mesna in children with osteosarcomas
11. Enantiomers of cyclophosphamide and iphosphamide
12. Dechloroethylation of ifosfamide and neurotoxicity
13. Ifosfamide induced subclinical tubular nephrotoxicity despite mesna
14. Tubular nephrotoxicity during long-term ifosfamide and mesna therapy
15. Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma
16. Metabolism of iphosphamide [2-(2-chloroethylamino)-3-(2-chloroethyl)tetrahydro-2H-1,3-2-oxazaphosphorine-2-oxide] and production of a toxic iphosphamide metabolite
17. Ifosfamide in pediatric malignancies
18. Ifosfamide neurotoxicity in children
19. Antitumor activity of optical isomers of cyclophosphamide, ifosfamide and trofosfamide as compared to clinically used racemates
20. Ifosfamide pharmacokinetics and neurotoxicity
21. The effect of route of administration and fractionation of dose on the metabolism of ifosfamide
22. Efficacy, toxicity, pharmacokinetics, and in vitro metabolism of the enantiomers of ifosfamide in mice
23. Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine
24. Fanconi syndrome after ifosfamide
25. Ifosfamide-induced Fanconi syndrome
26. Alkylating activity in serum, urine and CSF following high-dose ifosfamide in children
27. Quantitative Bestimmung von Cyclophosphamid, Ifosfamid und Trofosfamid sowie ihrer stabilen Metabolite auf der DC-Platte mit 4-Pyridinaldehyd-2-benzothiazolylhydrazon (PHB)
28. Ifosfamide-induced renal tubular defects
29. Disposition of ifosfamide in patients receiving ifosfamide infusion therapy for the treatment of cervical carcinoma
30. Ifosfamide, mesna, and encephalopathy
31. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna
32. Irreversible encephalopathy with ifosfamide/mesna
33. Nephrotoxicity of ifosfamide in children
34. Hypophosphataemic rickets after ifosfamide treatment in children
35. Nephrotoxicity associated with ifosfamide